ArticleACS biomaterials science & engineering
Nanofibrous Snake Venom Hemostat.
Article in ACS biomaterials science & engineering. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 60 citations in OpenAlex.
- Emerging self-assembled peptide hydrogels for enhanced wound healing.Nanomedicine (London, England) · 2025Review
- Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions.Signal transduction and targeted therapy · 2024Review
- Injectable Peptide Hydrogels Loaded with Murine Embryonic Stem Cells Relieve IschemiaBiomacromolecules · 2024Article
- Hemostasis Strategies and Recent Advances in Nanomaterials for Hemostasis.Molecules (Basel, Switzerland) · 2023Review
- Design of biopolymer-based hemostatic material: Starting from molecular structures and forms.Materials today. Bio · 2022Review
- Emerging hemostatic materials for non-compressible hemorrhage control.National science review · 2022Review
- Advances in the development and optimization strategies of the hemostatic biomaterials.Frontiers in bioengineering and biotechnology · 2022Review
- Preclinical Efficacy of Pro- and Anti-Angiogenic Peptide Hydrogels to Treat Age-Related Macular Degeneration.Bioengineering (Basel, Switzerland) · 2021Article
- Snake extract-laden hemostatic bioadhesive gel cross-linked by visible light.Science advances · 2021Article
- Evaluation of Injectable Naloxone-Releasing Hydrogels.ACS applied bio materials · 2020Article
- Peptide-based topical agents and intravenous hemostat for rapid hemostasis.RSC medicinal chemistry · 2020Review
- Functional Mining of theMolecules (Basel, Switzerland) · 2020Article
- Hemostatic agents for prehospital hemorrhage control: a narrative review.Military Medical Research · 2020Review
- Angiogenic peptide hydrogels for treatment of traumatic brain injury.Bioactive materials · 2020Article
- Perspective on the Therapeutics of Anti-Snake Venom.Molecules (Basel, Switzerland) · 2019Review
- Challenges in Translating from Bench to Bed-Side: Pro-Angiogenic Peptides for Ischemia Treatment.Molecules (Basel, Switzerland) · 2019Review
- Nanofibrous peptide hydrogel elicits angiogenesis and neurogenesis without drugs, proteins, or cells.Biomaterials · 2018Article
- Self-Assembling Multidomain Peptide Nanofibers for Delivery of Bioactive Molecules and Tissue Regeneration.Accounts of chemical research · 2017Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Controlling perioperative bleeding is of critical importance to minimize hemorrhaging and fatality. Patients on anticoagulant therapy such as heparin have diminished clotting potential and are at risk for hemorrhaging. Here we describe a self-assembling nanofibrous peptide hydrogel (termed SLac) that on its own can act as a physical barrier to blood loss. SLac was loaded with snake-venom derived Batroxobin (50
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.